X

Trial Profile

CAR-T Therapy in Relapsed or Refractory Haematopoietic and Lymphoid Malignancies

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 07 Dec 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Chimeric antigen receptor T cell therapy Hebei Senlang Biotechnology (Primary) ; Cyclophosphamide; Fludarabine
Indications Leukaemia; Lymphoma; Myeloma; Precursor B-cell lymphoblastic leukaemia-lymphoma
Focus Adverse reactions; Therapeutic Use
Sponsors Hebei Senlang Biotechnology

Most Recent Events

04 Dec 2018 Results (n=15) assessing the feasibility and safety of CD19 and CD22 Chimeric Antigen Receptors-Modified T Cell Cocktail for Therapy of B Cell Acute Lymphoblastic Leukemia, presented at the 60th Annual Meeting and Exposition of the American Society of Hematology
25 Apr 2017 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com